**Objectives:** We hypothesised that if IMB is indeed an RA-feature, then (1) at diagnosis its presence associates with other measures of local inflammation (synovitis, tenosynovitis and osteitis) and (2) it responds to DMARD therapy similarly as these other local inflammatory measures. These hypotheses were tested in a comprehensive MRI-study.

**Methods:** 157 consecutive early RA patients underwent unilateral contrast-enhanced 1.5T MRI of the foot at diagnosis. MRI assessments were performed for presence of IMB and for synovitis, tenosynovitis and osteitis in line with the RA MRI scoring system (summed as RAMRIS-inflammation). MRI scans at 4, 12 and 24 months were evaluated for presence and size of IMB-lesions in patients who had IMB at baseline and received early DMARD-therapy. Logistic regression was used for analyses at patient-level; generalised estimating equations were used for bursa-level analyses. Stratification for ACPA was performed.

**Results:** 69% of RA patients had ≥1 IMB. In multivariable analyses on bursa-level, presence of IMB was independently associated with local presence of synovitis and tenosynovitis (OR 1.69 [95% CI 1.12–2.57] and 2.83 [1.80–4.44], respectively), but not with osteitis. On patient-level, presence of IMB was most strongly associated with tenosynovitis (OR 2.92 [1.62–5.24]). During treatment with DMARDs, the average size of IMB-lesions decreased (Figure 1). This decrease was associated with decrease in RAMRIS-inflammation scores; most strongly with a decrease in synovitis but not in osteitis. Within ACPA-positive and ACPA-negative RA similar results were obtained.

**Conclusion:** IMB particularly accompanies inflammation of the synovial lining of joints and tendon-sheaths, both regarding simultaneous occurrence at diagnosis and simultaneous treatment-response. These findings suggest that IMB represents juxta-articular synovial inflammation and indeed is a hallmark of early RA.

**REFERENCES:**

**Disclosure of Interests:** None declared.

DOI: 10.1136/annrheumdis-2021-eular.303

---

**POS0022**

**Pharmacovigilance Pregnancy Data in a Large Population of Patients with Chronic Inflammatory Disease Exposed to Certolizumab Pegol: Pregnancy Outcomes and Confounders**

M. Clowse1, R. Fischer-Betz2, C. Nelson-Piercy3, A. Scheuerle4, T. Kumke5, B. Lauwersy6, R. Kaslfalv7, F. Föger8, 1Duke University Medical Center, Division of Rheumatology, Durham, United States of America; 2Heinrich Heine University Düsseldorf, Department for Rheumatology, Düsseldorf, Germany; 3Guy’s and St Thomas’ NHS Foundation Trust, Department of Women and Children’s Health, London, United Kingdom; 4UT Southwestern Medical Center, Department of Pediatrics, Division of Genetics and Metabolism, Dallas, United States of America; 5UCB Pharma, N/A, Monheim am Rhein, Germany; 6UCB Pharma, N/A, Brussels, Belgium; 7UCB Pharma, N/A, Slough, United Kingdom; 8Inselspital, University of Bern, University Clinic for Rheumatology, Immunology and Allergology, Bern, Switzerland

**Background:** Chronic inflammatory diseases (CID) in women of reproductive age are increasingly being treated with tumour necrosis factor inhibitors (TNFi), in line with recent guidelines. However, data on TNFi-exposed pregnancy outcomes are still limited. Certolizumab pegol (CZP), a PEGylated, Fc-free TNFi, has no/minimal placental transfer from mother to infant during the third trimester.

**Objectives:** To assess pregnancy outcomes from the UCB Pharmacovigilance safety database from over 1,300 prospectively reported pregnancies with maternal CZP exposure.

**Methods:** Details of CZP-exposed pregnancies from the UCB Pharmacovigilance safety database were reviewed up to November 1, 2020. Analysis was limited to prospectively reported cases with known pregnancy outcomes to avoid potential reporting bias. Confounders (specific CID, non-biologic medications and maternal infection) were evaluated using a multivariate stepwise regression model; results from the confounders analysis are reported as odds ratios (OR) with 95% confidence intervals (CI). Patients with missing information about presence or absence of confounders were excluded from the model.

**Results:** 1,392 prospectively reported pregnancies (1,425 fetuses) with maternal CZP exposure and known outcomes were reported (Figure 1). Mean gestational age at birth was 31.9 (5.1) years. Of these, 1,021/1,392 (73.3%) pregnancies had at least first-trimester CZP exposure and 547/1,392 (39.3%) were exposed during all trimesters. Overall, there were 1,259/1,425 (88.4%) live births, 150/1,425 (10.5%) abortions (miscarriages and terminations), 11/1,425 (0.8%) stillbirths, and 51/1,425 (0.4%) ectopic pregnancies. Congenital malformations were reported in 35/1,425 fetuses (2.5%) and in 901/1,259 live-born infants (2.4%); 25 (2.1%) congenital malformations were major according to the Metropolitan Atlanta Congenital Defects Program criteria.

There was no pattern of specific congenital malformations. Preterm births occurred in 124/1,259 (9.8%) live births, and 101/1,259 (8.0%) of infants had low birth weight (<2.5 kg). In the confounders analysis, reported corticosteroid use was independently associated with increased odds of preterm birth (OR [95% CI]: 2.1 [1.3–3.4]; p<0.005) and low birth weight (OR [95% CI]: 1.7 [1.0–2.9]; p<0.05), but decreased odds of abortion (OR [95% CI]: 0.5 [0.3–0.9]; p<0.05). Reported NSAID use was associated with increased odds of abortion (OR [95% CI]: 2.2 [1.2–4.0]; p<0.05), as was methotrexate/leflunomide use (OR [95% CI]: 3.2 [1.7–6.2]; p<0.005). Maternal infections were associated with increased odds of preterm birth (OR [95% CI]: 1.9 [1.1–3.5]; p<0.05). Finally, there was an association between a diagnosis of Crohn’s disease and odds of abortion (OR [95% CI]: 2.5 [1.5–4.1]; p<0.0005), and between rheumatoid arthritis and low birth weight (OR [95% CI]: 1.3 [1.1–3.3]; p<0.05).

**Conclusion:** This prospective analysis, including more than 1,000 pregnancies with CZP exposure in at least the first trimester, represents one of the largest cohorts of pregnancies with known outcomes in patients with CID. Our data confirm the impact of specific CID, concomitant drugs or comorbidities on pregnancy outcomes. In particular, additional use of corticosteroids was highlighted as a risk factor for preterm birth and low birth weight in our cohort of CZP-treated patients. No increase in adverse pregnancy outcomes or specific congenital malformations was observed in CZP-exposed pregnancies, compared to the general population, which offers further reassurance for women of childbearing age considering CZP treatment.

**References:**

**Figure.** Reports of pregnancies exposed to CZP identified in the UCB Pharmacovigilance safety database.

**Acknowledgements:** This study was funded by UCB Pharma. Editorial services were provided by Costello Medical.

**Disclosure of Interests:** Megan Clowse Consultant of: UCB Pharma, Grant/ research support from: Janssen, Pfizer, Rebecca Fischer-Betz Consultant of: AbbVie, BMS, Celgene, Chugai, Eli Lilly, Janssen, Novartis, Pfizer, Sanofi, UCB Pharma, Catherine Nelson-Piercy Consultant of: Alliance Pharma, UCB Pharma, Angela Scheuerle Consultant of: Antiretroviral Pregnancy Registry, Harmony Biosciences, IQVIA, ICON, NovoNordisk, PPD, Roche, Sanofi-Genzyme, Syneos, UCB Pharma, ViV, Thomas Kumke Shareholder of: UCB Pharma, Employee of: UCB Pharma, Bernard Lauwersy Employee of: UCB Pharma, Rachna Kaslfalv Employee of: UCB Pharma, Frauke Föger Speakers bureau: Mepha, Roche, UCB Pharma, Grant/research support from: UCB Pharma.

DOI: 10.1136/annrheumdis-2021-eular.577

**POS0023**

**Racial/Ethnic and Regional Differences in Multimorbidity Between Patients with Rheumatoid Arthritis and Comparators in a Large Nationwide US Study**

H.J. Dykhoff1, E. Myasoedova2,3, M. Peterson2, J. M. Davis III2, V. Kranzer2, C. Coffey4, T. Gunderson5, C.S. Crowson2,3, 1Mayo Clinic, Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Rochester, NY, 2Center for Outcomes Research, Mayo Clinic, Rochester, MN, 3Research in Arthritis and Musculoskeletal Diseases, Mayo Clinic, Rochester, MN, 4Department of Population Health, Kaiser Permanente Washington Health Research Institute, Seattle, WA, 5Institute of Medicine, Rheumatology, Science, and Quality, Mayo Clinic, Rochester, MN

**Objectives:** We used large national datasets to examine the racial/ethnic and regional differences in multimorbidity among patients with rheumatoid arthritis (RA) and their general population comparators in the United States (US), and to examine the potential impact of geographic factors on multimorbidity.

**Methods:** We used data from the US Renal Data System (USRDS), the Medicare Current Beneficiary Survey (MCBS), and the National Health and Nutrition Examination Survey (NHANES) to determine the socioeconomic, demographic, and geographic differences in multimorbidity among 1,161,322 US adults aged 18–64 years with self-reported RA and 2,994,775 general population comparators in the US from 2007 to 2017. We used the Charlson comorbidity index (CCI) to measure multimorbidity.

**Results:** The overall prevalence of multimorbidity was higher among adults with RA compared to general population comparators (31.7% vs. 26.8%, p<0.001). The prevalence of multimorbidity was highest among Hispanic and Asian adults with RA (34.1% and 33.7%, respectively) compared to White adults with RA (30.5%). The prevalence of multimorbidity was also higher among adults with RA compared to general population comparators in the South and Midwest compared to the Northeast and West (33.2% vs. 26.1%, p<0.001).

**Conclusion:** Racial/ethnic and geographic differences in multimorbidity were observed among adults with RA compared to general population comparators in the US. Further research is needed to understand the potential impact of geographic factors on multimorbidity among adults with RA.